Free Trial

Rhythm Pharmaceuticals (RYTM) News Today

$41.87
+1.19 (+2.93%)
(As of 06/21/2024 ET)
Rhythm Pharmaceuticals logo with Medical background
Healthcare of Ontario Pension Plan Trust Fund Has $6.98 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Healthcare of Ontario Pension Plan Trust Fund trimmed its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 14.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 151,843 shares of the company's sto
Rhythm Pharmaceuticals logo with Medical background
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 4.8%
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 4.8%
Rhythm Pharmaceuticals logo with Medical background
Perceptive Advisors LLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Perceptive Advisors LLC grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 465.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,154,110 shares of the company's stock after purchasing an addi
Rhythm Pharmaceuticals logo with Medical background
Virtu Financial LLC Takes Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Virtu Financial LLC purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 26,501 shares of the company's stock, valued at app
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Up 4.3%
Rhythm Pharmaceuticals logo with Medical background
Commodore Capital LP Sells 525,000 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Commodore Capital LP lowered its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 25.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,550,000 shares of the company's stock after selling 5
Rhythm Pharmaceuticals logo with Medical background
Bellevue Group AG Has $1.51 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Bellevue Group AG decreased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 55.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,869 shares of the company's stock after selling
Rhythm Pharmaceuticals logo with Medical background
TD Asset Management Inc Invests $1.74 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
TD Asset Management Inc purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 37,800 shares of the company's stock, valued at
Rhythm Pharmaceuticals logo with Medical background
Rafferty Asset Management LLC Has $5.59 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Rafferty Asset Management LLC cut its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 25.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 121,654 shares of the company's stock after sel
Rhythm Pharmaceuticals logo with Medical background
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 8.2%
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 8.2%
Rhythm Pharmaceuticals logo with Medical background
Artisan Partners Limited Partnership Makes New $12.48 Million Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Artisan Partners Limited Partnership acquired a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 271,421 shares of the company's stock, valued at approximately $12,
Rhythm Pharmaceuticals logo with Medical background
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stake Reduced by Clearbridge Investments LLC
Clearbridge Investments LLC cut its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 50.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,158 shares of the compan
Rhythm Pharmaceuticals logo with Medical background
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Primecap Management Co. CA
Primecap Management Co. CA reduced its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 2.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,052,648 shares of
Rhythm Pharmaceuticals, Inc. (RYTM)
Victory Capital Management Inc. Buys 162,247 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Victory Capital Management Inc. boosted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 809.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 182,297 shares of the com
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 3,984 Shares of Stock
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Joseph Shulman sold 3,984 shares of the stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $38.47, for a total value of $153,264.48. Following the completion of the sale, the insider now directly owns 30 shares of the company's stock, valued at approximately $1,154.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
National Bank of Canada FI Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
National Bank of Canada FI lifted its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 82.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 239,000 shares of the compa
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from Brokerages
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the compa
Rhythm Pharmaceuticals (NASDAQ:RYTM) PT Lowered to $79.00
Canaccord Genuity Group reduced their target price on shares of Rhythm Pharmaceuticals from $80.00 to $79.00 and set a "buy" rating for the company in a report on Wednesday.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Misses Expectations By $0.01 EPS
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) issued its earnings results on Tuesday. The company reported ($2.35) EPS for the quarter, missing the consensus estimate of ($2.34) by ($0.01). Rhythm Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 238.50%. The firm had revenue of $26.00 million during the quarter, compared to analyst estimates of $26.90 million. During the same quarter in the previous year, the business posted ($0.92) EPS. Rhythm Pharmaceuticals's revenue was up 126.1% compared to the same quarter last year.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Lowered to "Neutral" at Bank of America
Bank of America cut shares of Rhythm Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $49.00 to $42.00 in a research note on Wednesday.
Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call
The 3 Best Nasdaq Stocks to Buy in May 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $46.00 Price Target at Needham & Company LLC
Needham & Company LLC cut their price objective on Rhythm Pharmaceuticals from $50.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday.
Get Rhythm Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Discover AI Giants? (Ad)

Wondering which AI stocks are set to soar in 2024? We’ve identified the top 3, and we're excited to share them with you! Unlock immediate access to our exclusive report and discover... the key players and strategic insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.

[Download Your Free Report Now]

RYTM Media Mentions By Week

RYTM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RYTM
News Sentiment

1.17

0.71

Average
Medical
News Sentiment

RYTM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RYTM Articles
This Week

3

5

RYTM Articles
Average Week

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RYTM) was last updated on 6/23/2024 by MarketBeat.com Staff

From Our Partners